BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.

• Country Australia, New Zealand, United States
• organs None
• Specialty None

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination...

• Country None
• organs None
• Specialty None